Hospital
Northern Westchester Hospital Association
Northern Westchester Hospital Association was paid $7.58M by Medicaid between Jan 2018 and Dec 2024, across 138 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoNORTHERN WESTCHESTER HOSPITAL ASSOCIATION
MOUNT KISCO, NY 10549
MOUNT KISCO, NY 10549
33aNPI1912992215assigned 09/13/2005
33bProvider typePsychiatric Hospital Unit
28Total paid$7.58M
24GClaims170,527
24DCodes billed138
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in New York
Rank by total paid#10 of 33
Median peer was paid$171K
This provider vs. median44×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CUSACK, MICHELE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 934 | $13K | |
| 2019 | 8,246 | $390K | |
| 2020 | 22,008 | $1.04M | |
| 2021 | 35,525 | $1.53M | |
| 2022 | 36,521 | $1.55M | |
| 2023 | 37,434 | $1.69M | |
| 2024incomplete | 29,859 | $1.37M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 8,984 | 8,591 | $1.64M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 6,130 | 5,843 | $1.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.7% | 2,413 | 2,315 | $435K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.2% | 2,524 | 1,669 | $394K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.8% | 1,185 | 1,165 | $362K |
| 80053 | Comprehensive metabolic panel | 3.3% | 11,632 | 10,283 | $253K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 976 | 941 | $247K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 1,407 | 1,371 | $233K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.0% | 3,546 | 987 | $230K |
| C1889 | Implantable/insertable device, not otherwise classified | 2.7% | 321 | 319 | $205K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.0% | 1,411 | 1,409 | $152K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.9% | 1,003 | 954 | $144K |
126 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 491 | $139K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 1,909 | $121K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 542 | $119K |
| 59025 | Fetal non-stress test | 1.5% | 452 | $110K |
| J3490 | Unclassified drugs | 1.4% | 2,840 | $105K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 16,174 | $84K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.1% | 2,095 | $83K |
| 76641 | 1.1% | 1,205 | $83K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 475 | $75K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,373 | $73K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,653 | $69K |
| 86885 | <1% | 1,428 | $63K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 212 | $62K |
| 86900 | <1% | 1,742 | $59K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,519 | $59K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 38 | $50K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,269 | $47K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,186 | $47K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,457 | $42K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,104 | $40K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 532 | $40K |
| 86901 | <1% | 1,746 | $36K | |
| G0378 | Hospital observation service, per hour | <1% | 368 | $36K |
| 87631 | <1% | 492 | $32K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 498 | $29K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,233 | $27K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,404 | $26K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 3,845 | $24K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,947 | $24K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,333 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,787 | $19K |
| 93975 | <1% | 38 | $19K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 12 | $18K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,056 | $17K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,568 | $15K |
| 0225U | <1% | 1,186 | $15K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 97 | $15K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,518 | $15K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 70 | $13K |
| 76830 | Ultrasound, transvaginal | <1% | 206 | $13K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 223 | $12K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,265 | $11K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 125 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 782 | $11K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,109 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 725 | $10K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,400 | $9K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 42 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,205 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,643 | $8K |
| 85610 | <1% | 2,443 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,489 | $8K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 145 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 629 | $7K |
| 83735 | <1% | 1,523 | $7K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 706 | $7K |
| 77065 | Tomosynthesis, mammo | <1% | 70 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,940 | $6K |
| 97161 | <1% | 46 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,243 | $5K |
| 87486 | <1% | 128 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $5K |
| 84100 | <1% | 931 | $5K | |
| 86769 | <1% | 267 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 113 | $4K |
| 87468 | <1% | 113 | $4K | |
| 84703 | <1% | 3,078 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 357 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,154 | $3K |
| C1769 | Guide wire | <1% | 27 | $3K |
| 77066 | Tomosynthesis, mammo | <1% | 27 | $3K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 257 | $3K |
| 87581 | <1% | 128 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 151 | $2K |
| 87484 | <1% | 113 | $2K | |
| 88304 | <1% | 28 | $2K | |
| 80061 | Lipid panel | <1% | 132 | $2K |
| 85730 | <1% | 1,950 | $2K | |
| 80320 | <1% | 442 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 132 | $2K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 24 | $2K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 34 | $2K |
| 81001 | <1% | 3,069 | $1K | |
| 84439 | <1% | 95 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 188 | $1K |
| 76642 | <1% | 50 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 28 | $976.45 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 26 | $951.99 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 111 | $940.35 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 52 | $898.15 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 164 | $872.55 |
| 83615 | <1% | 186 | $860.22 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 14 | $844.92 |
| 84484 | <1% | 1,606 | $786.65 | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 57 | $744.28 |
| 83690 | <1% | 1,681 | $713.30 | |
| 81003 | <1% | 1,902 | $628.98 | |
| 86140 | <1% | 285 | $588.60 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 14 | $519.17 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 232 | $506.34 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 28 | $486.15 |
| 86780 | <1% | 56 | $469.56 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 259 | $432.40 |
| 88312 | <1% | 13 | $354.42 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 52 | $308.55 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 19 | $251.90 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 94 | $248.29 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 54 | $235.68 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 127 | $192.40 |
| 82962 | <1% | 434 | $184.36 | |
| 86618 | <1% | 184 | $176.58 | |
| 85379 | <1% | 232 | $154.80 | |
| 85652 | <1% | 153 | $143.99 | |
| 87040 | <1% | 655 | $140.71 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 71 | $135.31 |
| 87070 | <1% | 50 | $115.20 | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 18 | $113.70 |
| 85651 | <1% | 25 | $92.22 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 16 | $63.20 |
| 87207 | <1% | 140 | $53.64 | |
| 83605 | 0% | 29 | $0.00 | |
| 85027 | 0% | 13 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 18 | $0.00 |
| 85007 | 0% | 13 | $0.00 | |
| 84145 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCUSACK, MICHELE (EXECUTIVE VICE PRESIDENT & CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.